REHOVOT, Israel, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today financial results for the three and six months ended June 30, 2017.
Clinical, business and corporate developments for the three months ended June 30, 2017 and to date:
On August 3, 2017 we announced the dosing of the first patient in the third Phase 3 clinical trial for Minocycline Foam FMX101 (Study FX2017-22) for the treatment of moderate-to-severe acne.
